Clinical Trial: BEX101 in B-cell Non-Hodgkin's Lymphoma

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07882641) titled 'BEX101 in B-cell Non-Hodgkin's Lymphoma' on Oct. 12.

Brief Summary: BEX101 injection is an extracorporeal anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This single-arm, open-label, phase I/II clinical study is designed to evaluate the safety and efficacy of BEX101 injection in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) .

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Non-Hodgkin's Lymphoma

Intervention: BIOLOGICAL: BEX101 injection

BEX101 injection is an extracorporeal anti-CD19 CAR-T cell therapy product.

Recruitment Status: RECRUITING

Sponsor:...